RXRA and essential thrombocythemia: In conclusion, this study shows that type 1 and type 2 mutant calreticulins could lead to the overexpression of RXRA in patients with ET and points to the need for future research testing retinoids and other drugs targeting RXRα for the treatment of these patients.